Refractory, metastatic squamous cell Non-small cell lung cancer
Drug | Drug Name | Drug Description |
---|---|---|
DB08916 | Afatinib | An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB08916 | Afatinib | Epidermal growth factor receptor | target |
DB08916 | Afatinib | Receptor tyrosine-protein kinase erbB-2 | target |
DB08916 | Afatinib | Receptor tyrosine-protein kinase erbB-4 | target |
DB08916 | Afatinib | P-glycoprotein 1 | transporter |
DB08916 | Afatinib | ATP-binding cassette sub-family G member 2 | transporter |
Drug | Drug Name | Phase | Status | Count |
---|